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Abstract Recent advances in our understanding of the
biology of muscle, and how anabolic and catabolic stimuli
interact to control muscle mass and function, have led to
new interest in the pharmacological treatment of muscle
wasting. Loss of muscle occurs as a consequence of
several chronic diseases (cachexia) as well as normal
aging (sarcopenia). Although many negative regulators
[Atrogin-1, muscle ring finger-1, nuclear factor-kappaB
(NF-κB), myostatin, etc.] have been proposed to enhance
protein degradation during both sarcopenia and cachexia,
the adaptation of mediators markedly differs among these
conditions. Sarcopenic and cachectic muscles have been
demonstrated to be abundant in myostatin- and apoptosis-
linked molecules. The ubiquitin–proteasome system (UPS)
is activated during many different types of cachexia
(cancer cachexia, cardiac heart failure, chronic obstructive
pulmonary disease), but not many mediators of the UPS
change during sarcopenia. NF-κB signaling is activated in
cachectic, but not in sarcopenic, muscle. Some studies
have indicated a change of autophagic signaling during
both sarcopenia and cachexia, but the adaptation remains
to be elucidated. This review provides an overview of the
adaptive changes in negative regulators of muscle mass in
both sarcopenia and cachexia.
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Loss of muscle is a serious consequence of many chronic
diseases and of aging itself because it leads to weakness,
loss of independence, and increased risk of death. Unfor-
tunately, the field suffers from having more definitions than
therapies; muscle wasting is an inevitable part of aging,
where it is known as sarcopenia [1]. Muscle loss is also
common in most organ failure diseases—heart failure, liver
or renal failure, chronic obstructive pulmonary disease
(COPD)—and in some types of cancer. In such settings, it
is known as cachexia [2]. Another term commonly used is
wasting, such as AIDS wasting, known in Africa as slim
disease [2]. Of course, muscle wasting is also inevitable
during starvation.
In cases of simple disuse, such as when there is a cast in
place or when a patient is subjected to extended bed rest, the
term used is simply muscle atrophy, which is also used to
describe focal muscle loss, as seen in a variety of compression
syndromes or when there is motor neuron injury or disease.
Also, for some inflammatory myopathies, atrophy is used to
describe the loss of muscle mass. Common to all these
conditions is the fact that the muscle itself is genotypically
normal, in contrast to dystrophies in which a genetic mutation,
usually but not always in a structural protein, causes an eventual
loss of muscle mass due to the degeneration of muscle fibers.
A loss of more than 40% of body cell mass is fatal [3].
Although the treatment of muscle wasting due to starvation
is simple in principle, feeding the patient, it can be
complicated by metabolic derangements known as refeed-
ing syndrome [4]. However, for muscle wasting due to
sarcopenia or cachexia, the only effective treatment has
been a combination of adequate dietary protein, energy, and
progressive resistance exercise [5]. This approach, although
clearly efficacious in clinical trials, has limited effective-
ness because of difficulties with expanding exercise to the
level of a public health intervention. In particular, the effect
of exercise training to sarcopenia and cachexia is described
clearly on the recent excellent review by Lenk et al. [6].
A major barrier to the effective management of skeletal
muscle wasting is the inadequate understanding of its
underlying biological mechanisms. Therefore, in this
review, we will concentrate on specific alterations discussed
in the current literature that are present in the skeletal
muscle of both muscle wasting disorders. In addition, we
will focus on the adaptive changes in negative regulators
[ubiquitin–proteasome, myostatin, tumor necrosis factor-α
(TNF-α), etc.] for muscle mass.
2 The characteristics of sarcopenia and cachexia
2.1 Sarcopenia
Aging is associated with a progressive decline of muscle
mass, quality, and strength, a condition known as sarcope-
nia [7]. The term sarcopenia, coined by I. H. Rosenberg,
originates from the Greek words sarx (flesh) and penia
(loss). Although this term is applied clinically to denote
loss of muscle mass, it is often used to describe both a set
of cellular processes (denervation, mitochondrial dysfunc-
tion, inflammation, and hormonal changes) and a set of
outcomes such as decreased muscle strength, decreased
mobility and function [8], increased fatigue, a greater risk
of falls [9], and reduced energy needs. Estimates of the
prevalence of sarcopenia range from 13% to 24% in adults
over 60 years of age to more than 50% in persons aged
80 years and older [8]. Von Haehling et al. [10] have also
estimated the prevalence at 5–13% for elderly people aged
60–70 years and 11–50% for those aged 80 years or above.
The estimated direct healthcare costs attributable to sarco-
penia in the USA in 2000 were US $18.5 billion (US $10.8
billion for men, US $7.7 billion for women), which
represented about 1.5% of total healthcare expenditures
for that year [11].
Lean muscle mass generally contributes up to ∼50% of
total body weight in young adults, but declines with aging
to 25% at 75–80 years old [12, 13]. The loss of muscle
mass is typically offset by gains in fat mass. The loss of
muscle mass is most notable in the lower limb muscle
groups, with the cross-sectional area of the vastus lateralis
being reduced by as much as 40% between the age of 20
and 80 years [14]. On a muscle fiber level, sarcopenia is
characterized by specific type II muscle fiber atrophy, fiber
necrosis, and fiber type grouping [14–17]. In elderly men,
Verdijk et al. [16] showed a reduction in type II muscle
fiber satellite cell content with aging. Although various
investigators support such an age-related decrease in the
number of satellite cells [16–20], some reports [21, 22]
indicate no such change. In contrast, most studies point to
an age-dependent reduction in muscle regenerative capacity
due to reduced satellite cell proliferation and differentiation.
Several possible mechanisms for age-related muscle
atrophy have been described; however, the precise contri-
bution of each is unknown. Age-related muscle loss is a
result of reductions in the size and number of muscle fibers
[23] possibly due to a multifactorial process that involves
physical activity, nutritional intake, oxidative stress, and
hormonal changes [10, 24, 25]. The specific contribution of
each of these factors is unknown, but there is emerging
evidence that the disruption of several positive regulators
(Akt and serum response factor) of muscle hypertrophy
with age is an important feature in the progression of
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sarcopenia [26–29]. In contrast, many investigators have
failed to demonstrate an age-related enhancement in levels
of common negative regulators (Atrogin-1, myostatin, and
calpain) in senescent mammalian muscles. Currently
available data show that resistance training, myostatin
signaling inhibition, the ingestion of amino acids, treatment
with testosterone or growth hormone (GH), and CR appears
to counteract sarcopenia [27, 28]. Resistance training in
combination with amino acid-containing nutrition would be
the best candidate to attenuate age-related muscle wasting
and weakness.
2.2 Cachexia
In general, cachexia is a complication of diseases such
as heart failure, COPD, and cancer. A lack of
agreement exists concerning a precise clinical definition
of cachexia [30], but cachexia can be defined as a
wasting syndrome describing the progressive loss of both
adipose and skeletal muscle tissue in concert with severe
injury and chronic or end-stage malignant and infectious
diseases [31]. In addition to reducing the patient’s quality
of life (e.g., strength, endurance, and probably susceptibility
to other disease processes), progression of body wasting
has poor prognostic implications. Although the loss of
muscle mass clearly can be due to tumor-derived factors,
their role is complicated by the associated anorexia, the
decreased nutrient supply, and the resulting endocrine
changes (e.g., insulin deficiency, increased glucocorticoids,
TNF-α, and TWEAK) [32].
Cancer cachexia is a wasting that arises during the
course of most cancers, most often in incurable patients
toward the end stages of life. Although the etiopathogenesis
of cancer cachexia is poorly understood, multiple biologic
pathways are known to be involved, including tumor-
specific proteolysis-inducing factor (PIF) [32]. Cytokines
that are important in the initiation of the acute phase
response have also been implicated in the genesis of cancer
cachexia [33] or the result rather than the cause of cancer
cachexia. In particular, TNF-α has been shown to have a
direct catabolic effect on skeletal muscle and produces
muscle atrophy through the ubiquitin–proteasome system
(UPS) [34]. There are currently no agents approved for the
treatment of cancer cachexia. However, a number of agents
are used off-label to treat the condition, for example,
cannabinoids, corticosteroids, and nutritional supplements
[32, 35]. However, a significant unmet need prevails in the
cancer cachexia market, meaning most patients do not
receive any therapy.
Cardiac heart failure (CHF) is a major public health
problem in Western countries. Its incident has risen steadily
from 0.02 per 1,000 people per year among those aged 25–
34 years to 11.6 per 1,000 among those aged 85 years or older.
Using data from studies of left ventricular dysfunction, Anker
et al. [36] proposed defining cardiac cachexia as a docu-
mented non-edematous weight loss of > 6% of the previous
normal weight observed over a period of > 6 months. Unlike
other types of cachexia, cardiac cachexia is characterized
primarily by loss of type I muscle fibers. Interestingly, it can
be improved with exercise treatment, which has a major
clinical benefit in cardiac cachexia without any material
effect on cardiac output per se [37].
Evidence has strongly suggested that hypoxia can induce
muscle atrophy. It is known that chronic exposure to high-
altitude hypoxia [38] can cause a reduction of muscle fiber
size and loss of skeletal muscle mass in mountaineers.
COPD is characterized by airflow limitation. During the
past 10 years, COPD has emerged as a multi-organ system
disease [39]. Besides primary effects in the lung, COPD as
a chronic disease has secondary effects on other systems,
including the skeletal muscle. Specifically, COPD is
characterized by skeletal muscle dysfunction and atrophy
[40]. One of the major problems of patients with COPD is
exercise intolerance, which in turn leads to muscle wasting.
Muscle wasting should be considered a serious complica-
tion of COPD that has important implications for survival.
Systemic inflammation, i.e., increased muscle wasting, in
particular is a serious complication in COPD. COPD
patients have a more sedentary lifestyle than normal
patients. In one study, COPD patients spent 64% of their
time sitting or lying down compared with age-matched
healthy individuals who spent more than half of their time
walking or standing [39].
3 Negative regulators of skeletal muscle mass
At least four major proteolytic pathways (lysosomal, Ca2+-
dependent, caspase-dependent, and ubiquitin/proteasome-
dependent) operate in the skeletal muscle and may be
altered during aging, thus contributing to sarcopenia. The
lysosomal and proteasomal systems lead to an exhaustive
degradation of cell proteins into amino acids or small
peptides, whereas the Ca2+-dependent and caspase systems
can perform only limited proteolysis owing to their
restricted specificity.
The endosome–lysosome system is relatively nonselec-
tive and mostly involved in the degradation of long-lived
proteins [41]. Lysosomal autophagic degradation has been
reported to be induced in skeletal muscle by a 6-h nutrient
starvation [42], whereas autophagins, a class of cysteine
proteases putatively involved in the formation of autopha-
gosomes, are particularly abundant in the skeletal muscle
[43]. Recently, autophagy-related genes have been shown
to be hyperexpressed during muscle atrophy induced by
denervation or fasting [44–46].
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The ubiquitin–proteasome system, initially described as
relevant to the catabolism of regulatory or damaged
proteins, is also involved in bulk protein degradation, at
least in the skeletal muscle. In particular, the identification
of muscle-specific components of E3 ubiquitin ligases has
improved knowledge of the regulation of the ubiquitin–
proteasome system in skeletal muscle [47].
The Ca2+-dependent system comprises several cystein
proteases called calpains and a physiological inhibitor
named calpastatin. Calpains affect only a limited proteol-
ysis on their substrates (i.e., protein kinase C, calcineurin,
and titin), resulting in irreversible modifications that lead to
changes in activity or to degradation via other proteolytic
pathways [48, 49].
Finally, caspases, a family of cysteine protease, are
mostly known for their role in the execution of apoptosis.
Whether caspases are relevant to the regulation of skeletal
muscle mass still remains to be elucidated [50, 51].
3.1 Ubiquitin–proteasome system
The ATP-dependent UPS is essential for regulating protein
degradation [52]. In eukaryotic cells, most proteins in the
cytosol and nucleus are degraded via the UPS. The
degradation of a protein via the UPS involves two steps:
(1) tagging of the substrate by covalent attachment of
multiple ubiquitin molecules and (2) degradation of the
tagged protein by the 26S proteasome complex with the
release of a free and reusable ubiquitin [53]. In a variety of
conditions such as cancer, diabetes, denervation, uremia,
sepsis, disuse, and fasting, skeletal muscles undergo
atrophy through the degradation of myofibrillar proteins
via the UPS [54]. The fact that ubiquitin and proteasomes
have been implicated in many disease states suggests that
these inhibitors have therapeutic potential.
Ubiquitin, composed of 76 amino acids, is an 8.45-
kDa protein that is highly conserved in nearly all
eukaryotes. The ubiquitination of proteins is regulated
by at least three enzymes: ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzyme (E2), and ubiquitin
ligase (E3) [55]. Kwak et al. [56] suggested that the 14-
kDa ubiquitin-conjugating enzyme E214K and the ubiq-
uitin ligase E3 are particularly important for the degrada-
tion of muscle proteins. Indeed, recent findings assert that
muscle atrophy in these conditions shares a common
mechanism in the induction of the muscle-specific E3
ubiquitin ligase atrophy gene-1 (Atrogin-1) and muscle
ring finger-1 (MuRF-1) [47, 57, 58]. The labeled proteins
are then fed into the cells’ “waste disposers,” the so-called
proteasomes, where they are chopped into small pieces
and destroyed [59].
The proteasome is a highly conserved, intracellular,
multi-catalytic proteinase complex [60] which can catalyze
the cleavage of peptide bonds on the carboxyl side of basic,
acidic, and hydrophobic amino acid residues in both natural
peptides and synthetic substrates [61]. The 26S proteasome
is composed of a 19S cap-shaped regulatory particle and a
20S catalytic core particle. X-ray crystallography of the 26S
proteasome revealed the following: (1) the 19S proteasome
is made up of 18 subunits which control the recognition,
deubiquitination, and unfolding of protein substrates prior
to its translocation into the 20S proteasome [62]; (2) the
cylindrically shaped 20S proteasome is composed of two
copies of 14 different subunits, arranged as (α1–α7,
β1–β7)2 with four stacked rings.
In the skeletal muscle, anabolic signals influence protein
synthesis and accumulation by activating phosphatidylinositol-
3-kinase (PI3K) which is involved in the Akt-mTOR
(mammalian target of rapamycin) signaling pathway leading
to protein anabolism [63, 64]. Interestingly, the activation of
PI3K is also associated with the phosphorylation, and
therefore inactivation, of forkhead box O (FOXO) [58], a
transcription factor known to participate in the transcription
of Atrogin-1 and MuRF-1.
3.1.1 The UPS in aged muscle
In a variety of conditions such as cancer, diabetes,
denervation, uremia, sepsis, disuse, and fasting, skeletal
muscles undergo atrophy through the degradation of
myofibrillar proteins via the UPS [54, 57]. Recent advances
assert that muscle atrophy in these conditions shares a
common mechanism in the induction of the muscle-specific
E3 ubiquitin ligases Atrogin-1 and MuRF-1 [58, 65, 66].
Only very indirect measurements (small increases in
mRNA levels encoding some components of the UPS
[67–69] or ubiquitin–conjugate accumulation) in old
muscles of rodents or humans suggested a modest activa-
tion of this pathway. Atrogin-1 and/or MuRF-1 mRNA
levels in aged muscle are reportedly increased [70–72] or
unchanged [73, 74] in humans and rats, or decreased in rats
[73, 75, 76]. Even when the mRNA expression of these
atrogenes increased in sarcopenic muscles, it was very
limited (1.5- to 2.5 fold) as compared with other catabolic
conditions (10-fold).
Although various findings have been made regarding the
mRNA levels of both ubiquitin ligases in aged mammalian
muscle, the examination of protein levels in sarcopenic
muscles did not support age-related increases in the mRNA
of several ubiquitin ligases. For instance, a descriptive
analysis using muscle samples (n=10) by Edström et al.
[76] indicated the marked upregulation of phosphorylated
Akt and FOXO4 in the gastrocnemius muscle of aged
female rats, probably contributing to the downregulation of
Atrogin-1 and MuRF-1 mRNA. This result is further
supported by the more recent finding of Léger et al. [77]
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who, using human subjects 70 years old, demonstrated a
decrease in nuclear FOXO1 and FOXO3a by 73% and
50%, respectively, although they did not recognize an
significant age-dependent change in the expression of
Atrogin-1 and MuRF-1 mRNA. Since Goldberg’s group
[78] has defined the rapid and transient expression of
Atrogin-1 and MuRF-1, the mRNA levels of these
atrogenes would not necessarily correspond with those of
proteins in various conditions. Furthermore, the major
peptidase activities of the proteasome (i.e., the
chymotrypsin-like, trypsin-like, and caspase-like activi-
ties) were always reduced (as reported in other tissues)
[79] or unchanged with aging [70, 79, 80]. In contrast,
Altun et al. [72] recently found that the hindlimb muscles
of aged (30-month-old) rats contained two to threefold
more 26S proteasomes than those of adult (4-month-old)
controls. 26S proteasomes purified from muscles of aged
and adult (control) rats showed a similar capacity to
degrade peptides, proteins, and a ubiquitinated substrate,
but differed in the levels of proteasome-associated
proteins (e.g., the deubiquitinating enzyme USP14).
Although the activities of many other deubiquitinating
enzymes were greatly enhanced in the aged muscles,
levels of polyubiquitinated proteins were higher than in
the adult animals. Further systematic study (more frequent
time points) remains to be conducted using several
mammalian species because it is unclear whether the
UPS contributes to the establishment of sarcopenia. Since
no attempt to block sarcopenia-related atrophy and/or loss
of muscle fiber in mice and humans has been successful
[81], activation of the UPS would contribute little to
sarcopenic symptoms.
3.1.2 UPS in skeletal muscle of cachexia
Studies with animal models of cancer cachexia, as well as
in cancer patients, suggest that the UPS plays a prominent
role in the degradation of myofibrillar proteins, particularly
in patients with a weight loss of > 10% [82]. Increased
protein degradation by the UPS is implicated in skeletal
muscle wasting in cachectic conditions [83, 84]. The
expression of mRNA for both α- and β-proteasome
subunits was increased in the gastrocnemius muscle of
weight-losing mice bearing the MAC16 adenocarcinoma
[85]. Several experimental models of cancer cachexia [for
example AH-130, colon 26 (C26), Lewis lung carcinoma]
reported increased UPS activity as well as the over-
expression of both Atrogin-1 and MuRF-1 [86, 87]. The
expression of MuRF-1 in muscle after cancer cachexia has
recently been shown to be regulated by TNF receptor-
associated factor (TRAF) 6-dependent signaling [88]. In
CHF, diaphragm weakness is associated with myosin loss
and activation of the UPS [89]. In those cachectic states
investigated to date, UPS activity is upregulated in the
skeletal muscle; the transcript levels for UPS members are
also upregulated 8-, 2-, 40-, and 8-fold for ubiquitin, E2
ubiquitin-conjugating enzymes, E3 ubiquitin ligases, and
subunits of the 26S proteasome, respectively [83, 90, 91].
3.2 Autophagy-dependent signaling
Autophagy (derived from Greek and meaning “to eat
oneself”) occurs in all eukaryotic cells and is evolutionarily
conserved from yeast to humans [92]. Autophagy is a
ubiquitous catabolic process that involves the bulk degra-
dation of cytoplasmic components through a lysosomal
pathway [93–95]. This process is characterized by the
engulfment of part of the cytoplasm inside double-
membrane vesicles called autophagosomes. Autophago-
somes subsequently fuse with lysosomes to form autopha-
golysosomes in which the cytoplasmic cargo is degraded
and the degradation products are recycled for the synthesis
of new molecules [96]. The turnover of most long-lived
proteins, macromolecules, biological membranes, and
whole organelles, including the mitochondria, ribosomes,
the endoplasmic reticulum and peroxisomes, is mediated by
autophagy [97].
Three major mechanisms of autophagy have been
described: (1) microautophagy, which destroys only a
small portion of the cytoplasm, proteins, and maybe
glycogen in mammals [98]; (2) chaperone-mediated
autophagy, in which soluble proteins with a particular
pentapeptide motif are recognized and transported across
the lysosomal membrane for degradation; and (3) macro-
autophagy, in which a portion of the cytoplasm, including
subcellular organelles, is sequestered within a double-
membrane-bound vacuole that ultimately fuses with a
lysosome [99].
Noglaska et al. [100] suggested the prominent accu-
mulation of p62/SQSTM1, an autophagy-regulating pro-
tein, in the muscle fibers of patients with sporadic
myositis. p62/SQSTM1 interacts with the autophagosome
membrane microtubule-associated protein light chain (LC3)
protein which facilitates the delivery of its polyubiquitinated
cargo for lysosomal degradation [101, 102]. Interestingly, that
the UPS and the lysosomal–autophagy system in the skeletal
muscle are interconnected was suggested by the reports of
Mammucari et al. [44] and Zhao et al. [103]. Both studies
identified FOXO3 as a regulator of the lysosomal and
proteasomal pathways in muscle wasting. FOXO3 is a
transcriptional regulator of the ubiquitin ligases MuRF-1
and Atrogin-1. It has now been linked to the expression
of autophagy-related genes in skeletal muscle in vivo and
C2C12 myotubes [103]. More recently, Masiero et al.
[104] found an intriguing characteristic using muscle-
specific autophagy knockout mice. The atrophy, weakness,
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and mitochondrial abnormalities in these mice are also
features of sarcopenia.
3.2.1 A possible contribution of autophagic signaling
with age
A decline in autophagy during normal aging has been
described for invertebrates and higher organisms [105].
Inefficient autophagy has been attributed a major role in the
apparent age-related accumulation of damaged cellular
components, such as undegradable lysosome-bound lip-
ofuscin, protein aggregates, and damaged mitochondria
[106]. Interestingly, the degree of age-related changes in
autophagy appears to be organ-specific. While the auto-
phagic activity in liver declines with age [107], one group
suggests that autophagy is maintained in the heart of aged
rats [108]. Several recent studies have dealt with the
changes of autophagy with age in mammalian skeletal
muscle [109–112]. Compared with those in young male
Fischer 344 rats, amounts of Beclin-1, important for the
formation of preautophagosome structures [113], were
significantly increased in the plantaris muscles of senescent
rats [112]. In contrast, aging did not influence the amounts
of Atg7 and Atg9 proteins in rat plantaris muscle [112],
although these autophagy-linking proteins possess a crucial
role in the formation and expansion of the autophagosome
[114]. Indeed, Western blot analysis by Wohlgemuth et al.
[112] clearly showed a marked increase in the amount of
LC3 in muscle during aging. However, they could not
demonstrate an aging-related induction of the ratio of LC3-
II to LC3-I, a better biochemical marker to assess ongoing
autophagy [114]. In contrast, Wenz et al. [111] recognized a
significant increase in both the amount of phosphorylated
p65 and in the ratio of LC3-II to LC3-I during aging (3
versus 22 months) in the biceps femoris muscle of wild-
type mice. Intriguingly, no significant age-related increase
was observed in MCK-PGC-1α (peroxisome proliferator-
activated receptor-γ coactivator-1α) mice. Therefore, PGC-
1α would attenuate the autophagic process probably
through increased antioxidant defense and mitochondrial
biogenesis, and then preserved muscle integrity (e.g.,
protection from age-associated fibrosis). None of the
studies determining the transcript level of autophagy-
linked molecules found a significant increase with age
[109, 110, 112]. Therefore, not all contributors to autoph-
agy signaling seem to change similarly at both the mRNA
and protein levels in senescent skeletal muscle.
3.2.2 A possible contribution of autophagic signaling
to cachexia
Ryter et al. [115] have described increased autophagy in
clinical specimens of the lung from patients with COPD
relative to normal tissue, as evidenced by morphological
and biochemical markers. This evidence included the
electron microscopic evaluation of lung tissue morphology
as well as the increased expression and activation of
autophagic regulator proteins (i.e., LC3B, Beclin-1, Atg5,
Atg7). Only two recent studies have dealt with the changes
of autophagy during cachexia in mammalian skeletal
muscle. Using biopsy samples, Plant et al. [116] demon-
strated that there was no difference in the levels of Beclin-1
and LC3 transcripts in the quadriceps muscle of patients
with COPD compared with control individuals. In contrast,
endotoxin-induced cachexia seems to include the upregula-
tion of autophagic signaling. A significant increase in the
Atg7 and Atg12 proteins was observed in the soleus and
white vastus lateralis muscles as early as 8 h after the
injection of lipopolysaccharide (1 mg/kg). The amount of
Beclin-1 and the ratio of LC3-II to LC3-I also increased in
the soleus and white vastus lateralis muscles, respectively.
A more recent study [88] demonstrated that the depletion of
TRAF6 prevented tumor-induced muscle loss and the
upregulation of LC3B and Beclin-1 mRNA expression.
Therefore, the activation of autophagy under cachexia
seems to be regulated by TRAF6-dependent signaling.
3.3 Myostatin
Growth and differentiation factor 8, otherwise known as
myostatin, was first discovered during screening for novel
members of the transforming growth factor-β (TGF-β)
superfamily and was shown to be a potent negative
regulator of muscle growth [117]. Studies indicate that
myostatin inhibits cell cycle progression and reduces levels
of myogenic regulatory factors, thereby controlling myo-
blastic proliferation and differentiation during developmen-
tal myogenesis [118–120]. Mutations in myostatin can lead
to massive hypertrophy and/or hyperplasia in developing
animals, as evidenced by knockout experiments in mice.
Moreover, mouse skeletal muscle engineered to overex-
press the myostatin propeptide, the naturally occurring
myostatin inhibitor follistatin, or a dominant-negative form
of the Activin IIB receptor (ActRIIB—the main myostatin
receptor) [121] all display similar, if not greater, increases
in size [121]. Myostatin binds to and signals through a
combination of ActRIIA/B receptors on the cell membrane,
but has higher affinity for ActRIIB. On binding to ActRIIB,
myostatin forms a complex with a second surface type I
receptor, either activin receptor-like kinase (ALK) 4 or
ALK5, to stimulate the phosphorylation of receptor Smad
and the Smad2/3 transcription factors in the cytoplasm.
Then, Smad2/3 are translocated and modulate the nuclear
transcription of genes such as MyoD [122] via a TGF-β-
like mechanism. In contrast, FOXO1 and Smad2 appear to
control the differentiation of C2C12 myoblasts by regulat-
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ing myostatin mRNA and its promoters [122]. More
recently, the insulin-like growth factor I (IGF-I)-Akt-mTOR
pathway, which mediates both differentiation in myoblasts
and hypertrophy in myotubes, has been shown to inhibit
myostatin-dependent signaling. Blockade of the Akt-mTOR
pathway using siRNA to RAPTOR, a component of
TORC1 (TOR signaling complex 1), facilitates myostatin’s
inhibition of muscle differentiation because of an increase
in Smad2 phosphorylation [123]. In contrast, Smad2/3
inhibition promotes muscle hypertrophy partially dependent
on mTOR signaling [124].
Taking notice of the functional role in muscle mass by
myostatin, many researchers have conducted experiments
on inhibiting myostatin for treating various muscle disor-
ders. The use of neutralizing antibodies to myostatin
improved muscle disorders in rodent models of Duchenne
muscular dystrophy (mdx), limb girdle muscular dystrophy
2F (Sgcg−/−), and amyotrophic lateral sclerosis (SOD1G93A
transgenic mouse) [125–127]. Indeed, myostatin inhibition
using MYO-029 was tested in a prospective, randomized,
placebo-controlled US phase I/II trial in 116 adults with
muscular dystrophy such as Becker muscular dystrophy,
facioscapulohumeral muscular dystrophy, and limb girdle
muscular dystrophy [128]. Long-term administration of
MYO-029 at 1-, 3-, 10-, or 30-mg/kg doses had good safety
and tolerability, except for cutaneous hypersensitivity at 10
and 30 mg/kg. No improvements in muscle function were
noted, but some subjects had increased muscle fiber size.
The study concluded that the systemic administration of
myostatin inhibitors was relatively safe and that more
effective inhibitor of myostatin signaling should be consid-
ered to attenuate muscular dystrophy.
3.3.1 Myostatin signaling in sarcopenia
Myostatin levels increase with muscle atrophy due to
neuromuscular inactivity in mice and humans [129–131],
and with severe muscle wasting in HIV patients [132]. For
example, our recent study [130], using healthy university
students, showed significantly increased levels of myostatin
mRNA in muscle after the unilateral suspension of a
hindlimb for 2 weeks. Together, these studies suggest that
increased levels of myostatin lead to muscle wasting.
Unfortunately, there are only few studies that have
examined the changes of the myostatin level in sarcopenia.
These studies have yielded conflicting results such as
marked increases in humans at the mRNA and protein
levels [77], no change in mice at the protein level [133],
and a decrease in rats at the mRNA level [134].
Intriguingly, Carlson et al. [133] showed the enhanced
levels of Smad3, but not myostatin, TGF-β2, or follistatin,
in sarcopenic muscles of mice. The functional role of
myostatin in aged mammalian muscle seems to be revealed
by further descriptive analysis using other methods (e.g.,
immunofluorescence) and examining the adaptive changes
in downstream modulators (e.g., ActRIIB, Smad3) of
myostatin signaling.
Although it is ambiguous for the functional role in
myostatin to sarcopenia, many researchers have investi-
gated the effect of inhibiting myostatin to counteract
sarcopenia using animals. A lack of myostatin caused by
gene manipulation increased the number of satellite cells
and enlarged the cross-sectional area of predominant type
IIB/X fibers in tibialis anterior muscles of mice [135]. In
addition, these myostatin-null mice showed prominent
regenerative potential, including accelerated fiber remod-
eling after an injection of notexin [135]. Lebrasseur et al.
[136] reported several positive effects of 4 weeks of
treatment with PF-354 (24 mg/kg), a drug for inhibiting
myostatin, in aged mice. They found that PF-354-treated
mice exhibited significantly greater muscle mass (by 12%)
and increased performance such as treadmill time and
distance to exhaustion. Furthermore, PF-354-treated mice
exhibited decreased levels of phosphorylated Smad3 and
MuRF-1 in aged muscle. More recently, Murphy et al.
[137] showed, by way of once-weekly injections, that a
lower dose of PF-354 (10 mg/kg) significantly increased
the fiber cross-sectional area (by 12%) and in situ muscle
force (by 35%) of aged mice (21 months old). In addition,
this manner of PF-354 treatment reduced the markers of
apoptosis by 56% and reduced caspase3 mRNA by 65%.
Myostatin blockade enhances muscle protein synthesis
[138] by inhibiting the UPS which is controlled, in part,
by Akt [139, 140], although the mechanism has not been
apparently demonstrated. In contrast, microarray analysis
of the skeletal muscle of Mstn−/− mice showed an
increased expression of anti-apoptotic genes compared
with control mice [140]. These findings clearly highlight
the therapeutic potential of antibody-directed myostatin
inhibition for sarcopenia by inhibiting protein degradation
and/or apoptosis.
3.3.2 Myostatin signaling in cachexia
Increased signaling by the ActRIIB pathway has been
implicated in many cancers [141, 142]. The administration
of myostatin in vivo to adult mice induces profound muscle
loss analogous to that seen in human cachexia syndromes
[143]. In vitro studies showed that myostatin-induced
cachexia caused the activation of the UPS through a
FOXO1-dependent signaling [139]. Myostatin induction
was also recognized in an animal model of cardiac cachexia
such as the peri-infact zone in sheep [144] and a rat model
of volume overload induced by an aortocaval shunt [145].
As support to these findings, Heineke et al. [146]
demonstrated that cardiomyocyte-specific overexpression
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of myostatin significantly reduced both cardiac and
skeletal muscle mass. Furthermore, several recent reports
suggested that the upregulation of myostatin is involved
in the development of muscle atrophy associated with
COPD [116, 147]. For example, Hayot et al. [148] found
an increased skeletal muscle myostatin expression in
hypoxemic COPD patients (PaO2=64±2 mm Hg) com-
pared with that in healthy controls. Therefore, abundant
myostatin protein induces muscle atrophy in various
different cachexias.
The attenuation of myostatin-dependent signaling
markedly improves the muscle wasting of cachexia.
Skeletal muscle atrophy in heart failure was markedly
prevented by myostatin deletion from the heart but not
the skeletal muscle [148]. More recently, Zhou et al. [149]
indicated the therapeutic potential of blocking the myostatin
receptor, ActRIIB, on cancer cachexia. They utilized
various models of cancer cachexia models, including C26
tumor-bearing mice and inhibin-deficient mice, as well as
nude mice bearing human G361 melanoma and TOV-21G
ovarian carcinoma xenografts. Blockade of the ActRIIB
pathway using the decoy receptor (sActRIIB) completely
reversed the pathology and muscle atrophy caused by
cancer cachexia. Treatment with sActRIIB abolished the
activation of the UPS and the induction of atrophy-specific
ubiquitin ligases, probably due to the decreased phospho-
Smad2 and the increased inactivated (phospho)-FOXO3
and phospho-Akt proteins in cachectic muscles. Klimek et
al. [150] also showed that the use of a soluble ActRIIB
receptor increased mass by between 23% and 40%.
ActRIIB-Fc is not specific for myostatin and known
ActRIIB ligands include growth and differentiation factor-
11 and the activins [151]. Thus, the protective effect of
ActRIIB-Fc may be due to the inhibition of these other
targets, alone or with myostatin. Furthermore, Heineke et
al. [146] observed a therapeutic effect of an anti-myostatin
antibody (JA-16) to the atrophy of several skeletal muscles
occurring after cardiac cachexia caused by transverse aortic
constriction.
3.4 TNF-α and NF-κB signaling in sarcopenia
Inflammation may negatively influence skeletal muscle
through direct catabolic effects or through indirect mecha-
nisms (i.e., decreases in GH and IGF-I concentrations,
induction of anorexia, etc.) [152]. There is growing
evidence that higher levels of inflammatory markers are
associated with physical decline in older persons, possibly
through the catabolic effects of inflammatory markers on
muscle. In an observational study of more than 2,000 men
and women, TNF-α showed a consistent association with
declines in muscle mass and strength [153]. The impact of
inflammation on the development of sarcopenia is further
supported by a recently published animal study showing
that a reduction of low-grade inflammation by ibuprofen in
old (20 months) animals resulted in a significant decrease in
muscle mass loss [154]. An age-related disruption in the
intracellular redox balance appears to be a primary causal
factor of a chronic state of low-grade inflammation. More
recently, Chung et al. [155] hypothesized that abundant NF-
κB protein induced age-related increases in interleukin (IL)-
6 and TNF-α. Moreover, reactive oxygen species (ROS)
also appear to function as second messengers for TNF-α in
skeletal muscle, activating NF-κB either directly or indi-
rectly [156]. Indeed, a marked production of ROS has been
documented in muscle of the elderly [157, 158]. However,
it is not clear whether NF-κB signaling is enhanced with
age. Despite some evidence supporting enhanced NF-κB
signaling in type I fibers of aged skeletal muscle, direct
evidence for an increased activation and DNA binding of
NF-κB is lacking [159, 160]. For example, Phillips and
Leeuwenburgh [160] found that neither p65 protein
expression nor the binding activity of NF-κB was signif-
icantly altered in the vastus lateralis muscles of 26-month-
old rats despite the marked upregulation of TNF-α
expression in both blood and muscle. Upregulated TNF-α
expression in serum and muscle seems to enhance apoptosis
in the mitochondria, resulting in the loss of muscle fibers
[160–162]. It has been shown that TNF-α is one of the
primary signals inducing apoptosis in muscle.
3.4.1 PIF, TNF-α, and NF-κB in cachectic muscle
TNF-α, IL-1, IL-6, and interferon (IFN)-γ have been
implicated in cancer-related muscle wasting [163]. For
example, the transplantation of Chinese hamster ovary cells
transfected with the human TNF-α gene produced a
syndrome resembling cachexia, with progressive wasting,
anorexia, and early death [164]. Treatment with TNF-α
disrupted the regeneration of skeletal muscle because of a
marked delay in the expression of muscle differentiation
markers such as myogenin and neonatal myosin heavy
chain [165]. TNF-α, either on its own [166] or in
combination with IFN-r [167], causes the reduced expres-
sion of myosin heavy chain in cultured myotubes or whole
muscle possibly due to the MyoD-stabilizing, RNA-binding
protein HuR [168]. The enhanced production of nitric oxide
(NO) synthase by TNF-α/IFN-r led to HuR moving away
from the MyoD message, thereby causing MyoD mRNA
decay. In fact, the atrophic muscles in a rodent model of
cancer cachexia possessed low levels of MyoD [169]. The
NO induction by TNF-α/IFN-α in cachectic muscles seems
to be mediated by NF-κB-dependent signaling [168].
Several studies of cachexia have indicated enhanced NF-
κB signaling in skeletal muscle [170, 171], different from
sarcopenic muscle. For example, NF-κB DNA binding and
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transactivation potential have been demonstrated in atro-
phic muscle bearing C26 tumors [172, 173]. In addition, a
study using an injected decoy oligonucleotide to NF-κB
further supports the role of this transcription factor in
tumor-regulated muscle wasting [173]. Furthermore,
MuRF-1, a downstream mediator of the IKKβ/NF-κB
pathway, is more abundant in cachectic muscle [65, 174,
175]. In contrast, TNF-α, IFN-r, and IL-1β, known to be
increased in cachectic patients, are potent activators of
inducible NO synthase expression [176], which in turn
produces toxic levels of NO high enough to inhibit the key
enzymes of oxidative phosphorylation. More recent find-
ings showed cachexia-induced selective atrophy of glyco-
lytic muscles probably due to small amounts of catalase and
superoxide dismutase to inhibit oxidative stress [177].
PIF is a 24-kDa sulfated glycoprotein originally isolated
from cachexia-inducing MAC16 tumor cells using an
antibody cloned from splenocytes of mice bearing the same
tumor, but with a delayed cachexia [178]. This substance
was evident in the urine of weight-losing patients with a
variety of tumor types, including pancreatic, lung, breast,
ovary, rectum, colon, and liver cancer, but absent in urine
from patients without weight loss [179]. Unlike TNF-α, it
occurred without a depression of either food or water intake
and was a result of the specific depletion of lean body mass
[178]. There were specific reductions in the weight of
several skeletal muscles, but not the heart or kidney. Aside
from TNF-α and IL-1β, recent developments indicate that
NF-κB is also under the control of PIF [180]. Wyke and
Tisdale [181] showed that the activation of NF-κB in
C2C12 myotubes occurred through the phosphorylation and
degradation of IκB (inhibitor of NFκB)α, leading to the
nuclear translocation of the p50/p65 heterodimer. Although
this activation is relatively modest in comparison with
cytokine stimulation, it is sufficient to induce an ATP-
dependent proteasome activity because addition of the
IκBSR transdominant inhibitor of NF-κB inhibits the
proteasome in response to PIF treatment.
3.5 Apoptotic signaling in sarcopenic muscle
Several reports indicate that apoptosis is enhanced in aged
skeletal muscle, likely contributing to the development of
sarcopenia [182]. Apoptosis is an evolutionary conserved
process of programmed cell death, which is performed via a
systematic set of morphological and biochemical events,
resulting in cellular self-destruction without inflammation
or damage to the surrounding tissue. The execution of
apoptosis in skeletal muscle displays unique features due to
the multinucleated nature of myofibers. Therefore, apopto-
sis in myocytes may result in the elimination of individual
myonuclei and the surrounding portion of sarcoplasm,
without the dismantling of the entire fiber [183].
The mitochondria play an important part in apoptosis by
activating caspases (cystein-dependent, aspartate-specific
proteases) [184, 185]. Mitochondrial dysfunction can lead
to mitochondrial cytochrome c release [185]. In the
cytoplasm, cytochrome c, apoptotic protease activating
factor-1 , caspase-9, and dATP form an apoptosome which
can activate caspase-3, a key cell death protease. Importantly,
in the white gastrocnemius and soleus muscles of Fischer
344 rats, it was recently demonstrated that aging significantly
increased DNA fragmentation, and the amounts of cleaved
caspase-3 and pro-apoptotic Bax, and decreased anti-
apoptotic Bcl-2 protein content [186]. In addition, several
researchers [186, 187] have suggested that the mitochondrial
permeability transition pore could induce the release of
cytochrome c. Mitochondria are essential for proper cellular
functioning and viability, being the main site for energy
production and playing an essential role in the maintenance
of redox homeostasis [188]. MtDNA is especially prone to
oxidative damage [189], particularly in aged mammalian
muscles [190, 191], due to its proximity to the electron
transport chain, the lack of protective histones, and a less
efficient repair system compared with nuclear DNA [192].
Aside from mitochondria-mediated apoptosis, other
pathways of myonuclear apoptosis may be involved at an
advanced age. In particular, the death receptor-mediated
pathway, triggered by TNF-α, appears to be upregulated in
aged rodent muscles [160, 182]. Recent findings suggest
that apoptotic signaling is required for and precedes protein
degradation during muscle atrophy [193]. Although a clear
mechanistic link between myonuclear apoptosis and sarco-
penia is yet to be established, data from animal models
suggest that this link exists [161, 194]. Moreover, other
rodent studies indicate an association between myocyte
apoptosis and declines in muscle mass and strength [184].
Despite that most studies with animal models appear to
support a key role for apoptosis in age-related muscle
atrophy, evidence in humans is still scarce. A recent report
indicated increases in the expression of the mitochondrial
caspase-independent mediator apoptosis-inducing factor in
the semitendinousus muscle of middle-aged men relative to
younger controls [195]. This finding is consistent with
previously described data from animal experiments and
supports the involvement of mitochondria-driven apoptosis
in the development of sarcopenia.
3.5.1 Apoptotic signaling in cachectic muscle
Busquets et al. [196] have shown that, together with
myofibrillar protein loss, skeletal muscle of cachectic
tumor-bearing animals is subject to an important activation
of DNA fragmentation and, therefore, apoptosis. Interest-
ingly, they have found that different anti-cachectic treat-
ments resulted not only in a restoration of skeletal muscle
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protein content but also in an amelioration of apoptosis
[197]. For instance, formoterol (a β2-adrenergic agent)
treatment in tumor-bearing animals resulted in a dramatic
reduction of DNA fragmentation in skeletal muscle.
Several reports suggest that certain molecules involved
in signaling pathways that result in apoptosis can promote
or inhibit NF-κB activation in particular cell lines. Caspase-
8, Fas-associated death domain, caspase-8-like inhibitory
protein (cFLIP), TNF-α-related apoptosis-inducing ligand
receptors, and TNF-R1 activate NF-κB in a variety of cells
using a TRAF2/NF-κB-inducing kinase/IKK-dependent
pathway [197–199] that can be blocked by their inhibitors
or dominant-negative mutants [198, 200]. Cellular cFLIP is
a caspase-8 homologue devoid of protease activity and a
catalytically inactive caspase-like domain. cFLIP inhibits
procaspase-8 processing at the DISC in most cells, thus
inhibiting also the apoptosis induced by cancer cells [201].
Jiang and Clemens [201] studied the effect of secreted
factors (e.g., TNF-α) from different cancer cell lines on
myoblast differentiation in vitro. In their study, cFLIP
overexpression inhibited IL-1β or PC-3 or Mel media-
induced NF-κB activation in myoblast cells, thus promoting
the myogenic differentiation of myoblasts. The stable
expression of cFLIP yielded results similar to the stable
expression of IκBSR, a mutated form of IκBα that prevents
the activation of NF-κB. In contrast, the overexpression of
Bcl-xL enhanced NF-κB activation in myoblast cells, with
a further increase upon exposure to conditioned medium
from PC-3 cells. Bcl-xL is another anti-apoptotic protein
and is localized to the endoplasmic reticulum so as to
prevent the release of cytochrome c from the mitochondria
[202]. Although several studies have shown that both
cFLIP and Bcl-xL influence NF-κB activation and cell
survival in a variety of cell lines [197, 200], the two may
play a role in apoptosis via a different pathway, at least in
muscle cell lines [201]. Figure 1 provides an overview of
the adaptive changes in negative regulators for muscle mass
in sarcopenia and cachexia.
3.6 Anabolic hormones in sarcopenic muscle
Among hormonal changes that might be related to aging, a
primary role is likely had by the aging-related deficit of
anabolic hormones, promoting a milieu that favors catabo-
lism. This aging-related deficiency in the anabolic hormone
milieu takes several different forms, being relatively sudden
and dramatic in the case of estrogen in women, but more
gradual and steady for testosterone in men, and GH in both
genders [203–207]. Indeed, circulating GH levels decline
progressively after 30 years of age at a rate of ∼1% per year
[203]. In addition, there is evidence that the age-associated
decline in GH levels in combination with lower IGF-I levels
contributes to the development of sarcopenia [208].
IGF-I is perhaps the most important mediator of muscle
growth and repair [209] possibly by utilizing Akt-mTOR-
p70S6K signaling. Although the transgenic approach of
upregulating IGF-I expression in skeletal muscle would be
appropriate for inhibiting sarcopenia, the administration of
IGF-I to the elderly has resulted in controversial findings on
muscle strength and function [210]. GH treatment in elderly
subjects has also yielded conflicting results [27, 211]. The
ineffectiveness may be attributable to age-related insulin
resistance to amino acid transport and protein synthesis
[212] or a marked decrease in IGF-I receptors [213, 214]
and receptor affinity for IGF-I [215] in muscle with age. In
addition, reduced mRNA levels of the GH receptor in
skeletal muscle have been observed in older versus younger
healthy men, exhibiting a significant negative relationship
with myostatin levels [216]. Wilkes et al. [217] demon-
strated a reduced effect of insulin on protein breakdown in
the legs in older versus younger subjects, probably due to
the blunted activation of Akt by insulin. More comprehen-
sive reviews on insulin resistance in sarcopenia can be
found elsewhere [212].
Numerous studies of treatment with testosterone in the
elderly have been performed over the past few years [218–
221]. Systemic reviews of the literature [222] have
concluded that testosterone supplementation attenuates
several sarcopenic symptoms in humans, including the
decrease in muscle mass [219–221] and grip strength [218].
For instance, a recent study of 6 months of testosterone
supplementation in a randomized placebo-controlled trial
reported increased leg lean body mass and leg and arm
strength [223]. Although the mechanisms by which
testosterone increases skeletal muscle mass are poorly
understood, several modulators such as Notch-1, the
androgen receptor, and IGF-I acting via testosterone-
mediated signaling have been identified [224].
3.6.1 Anabolic hormones in cachectic muscle
Low concentrations of testosterone and anabolic hormones
are major contributors to cachexia-related wasting of
skeletal muscle. Up to 50% of men with metastatic cancer
prior to chemotherapy present with low testosterone levels
[225]. A reduction in testosterone might lead to a reduced
muscle strength and sexual function in both men and
women [226]. In addition, reduced levels of anabolic
hormones, such as testosterone and IGF-I, have been
observed in COPD patients [227–229]. Furthermore,
studies in patients with advanced heart failure and cardiac
cachexia have revealed a possible involvement of GH and
IGF-I in muscle catabolism. Elevated levels of GH with
inappropriate serum levels of IGF-I have been described in
cardiac cachexia [230]. Indeed, low levels of systematic
IGF-I have been associated with decreased leg muscle
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cross-sectional area and strength in CHF patients [231]. In
contrast, catabolic syndromes involving chronic inflamma-
tion, sepsis, or cancer show an altered GH/IGF-I axis most
probably due to a peripheral IGF-I deficiency because of an
impaired IGF-I response to GH [232]. Pro-inflammatory
cytokines such as TNF-α uncouple the GH/IGF-I axis
through suppression of the GH receptor [233].
Studies on the use of testosterone and testosterone
derivatives in cachexia patients have been limited largely to
cases of COPD and HIV/AIDS, where positive effects on
body weight, lean bodymass, and some functional parameters
have been documented [234–236]. The long experience with
testosterone use makes this hormone a therapeutic candidate
for use in cachectic patients. The limited number of trials that
have investigated the anabolic effect of testosterone in
cachectic subjects demonstrates a generally favorable effect
on body weight, lean body mass, and muscle strength with
an acceptable safety profile [234–236].
In a pilot study of malnourished patients with COPD by













































Fig. 1 Myostatin signals through the activin receptor IIB (Actr2b)
ALK4/5 heterodimer activate Smad2/3 with the consequent nuclear
translocation of Smad4 and blocking of MyoD transactivation in an
autoregulatory feedback loop. In both sarcopenic and cachectic
muscles, abundant activated Smad2/3 inhibit protein synthesis,
probably due to blocking of the functional role of Akt. In sarcopenic
muscle, Akt can block the nuclear translocation of FOXO to inhibit
the expression of Atrogin-1. In contrast, the impaired regulation of
FOXO by Akt results in the abundant expression of Atrogin-1 and the
consequent protein degradation in cachectic muscle. Although the
blood and muscle levels of TNF-α were increased in both muscle
wasting, the elevation of NF-κB occurs in cachectic but not sarcopenic
muscles. Both muscle wasting include the enhancement of apoptosis
signaling. IGF-I insulin-like growth factor I, IGF-IR IGF-I receptor,
PI3-K phosphatidylinositol 3-kinase, TORC1 component of TOR
signaling complex 1, Rheb Ras homolog enriched in brain, mTOR
mammalian target of rapamycin, eIF4E eukaryotic initiation factor 4E,
FOXO forkhead box O, IKK inhibitor of κB kinase, NF-κB nuclear
factor of kappa-B, MuRF1 muscle ring finger protein 1, TNF tumor
necrosis factor
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daily) caused substantial weight gain and improved
maximal inspiratory pressure. Although Burdet et al.
[238] also found a significant increase in free fatty mass
after 3 weeks of treatment with GH, none of the other
parameters (handgrip strength, etc.) improved. Furthermore,
in several trials, GH treatment failed to improve the clinical
status of CHF patients [239, 240]. A recombinant GH has
been approved by the U.S. Food and Drug Administration
for the treatment of HIV/AIDS wasting or pediatric chronic
kidney disease. Indeed, in several studies in cachectic
patients with HIV, recombinant GH has significantly
increased lean body mass, physical endurance, and quality
of life [241]. However, the effect is not very large and
treatment of the underlying disease with highly effective
antiretroviral agents has largely eliminated AIDS wasting as
a clinical problem in developed countries.
An indirect way in which GH secretion increases is
via GH secretagogues [242]. The prototype, ghrelin, is a
28-amino acid peptide mainly produced by cells in the
stomach, intestines, and hypothalamus [243]. When
released by neuroendocrine cells of the hypothalamus, it
binds to receptors on somatotropes and causes the release
of GH into the circulation. In contrast, ghrelin inhibits the
production of anorectic pro-inflammatory cytokines, including
IL-1β, IL-6, and TNF-α [244]. In addition, ghrelin
increases hunger by acting on hypothalamic feeding
centers and stimulating gastric emptying, which facilitates
increased food intake [245]. Because of their combined
anabolic effects on skeletal muscle and appetite, ghrelin
and low-molecular-weight agonists of the ghrelin receptor
are considered attractive candidates for the treatment of
cachexia [242].
Although glucocorticoids are useful adjuvants in the
treatment of cachexia because of their beneficial effects
on symptoms such as appetite, food intake, and a
sensation of well-being, their use should be confined to
the end stage of the disease, and limited to a few weeks,
because of their ability to induce atrophy of the skeletal
muscle, which primarily affects type II muscle fibers.
Glucocorticoids may play a role in the development of
cancer-related cachexia [246], although adrenalectomy
has been shown not to alter the course of cachexia in
other animal models [247]. The effect of glucocorticoids
on muscle atrophy is mediated by upregulation of the UPS
[248] and intramuscular myostatin expression. Intriguingly,
deletion of the myostatin gene prevented glucocorticoid-
induced muscle atrophy [249].
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